REFERENCES
1. Reck-Peterson SL, Redwine WB, Vale RD, Carter AP. The cytoplasmic dynein transport machinery and its many cargoes. Nat Rev Mol Cell Biol 2018;19:382-98.
2. Cianfrocco MA, DeSantis ME, Leschziner AE, Reck-Peterson SL. Mechanism and regulation of cytoplasmic dynein. Annu Rev Cell Dev Biol 2015;31:83-108.
3. Bercier V, Hubbard JM, Fidelin K, et al. Dynactin1 depletion leads to neuromuscular synapse instability and functional abnormalities. Mol Neurodegener 2019;14:27.
5. Konno T, Ross OA, Teive HAG, Sławek J, Dickson DW, Wszolek ZK. DCTN1-related neurodegeneration: Perry syndrome and beyond. Parkinsonism Relat Disord 2017;41:14-24.
6. Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455-6.
7. Farrer MJ, Hulihan MM, Kachergus JM, et al. DCTN1 mutations in Perry syndrome. Nat Genet 2009;41:163-5.
8. Zhang J, Wang H, Liu W, et al. A novel Q93H missense mutation in DCTN1 caused distal hereditary motor neuropathy type 7B and Perry syndrome from a Chinese family. Neurol Sci 2021;42:3695-705.
9. Dulski J, Cerquera-Cleves C, Milanowski L, et al. Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review. Eur J Neurol 2021;28:4010-21.
10. Tsuboi Y, Mishima T, Fujioka S. Perry disease: concept of a new disease and clinical diagnostic criteria. J Mov Disord 2021;14:1-9.
11. Dixit R, Levy JR, Tokito M, Ligon LA, Holzbaur EL. Regulation of dynactin through the differential expression of p150Glued isoforms. J Biol Chem 2008;283:33611-9.
12. Zhapparova ON, Bryantseva SA, Dergunova LV, et al. Dynactin subunit p150Glued isoforms notable for differential interaction with microtubules. Traffic 2009;10:1635-46.
13. Lloyd TE, Machamer J, O’Hara K, et al. The p150(Glued) CAP-Gly domain regulates initiation of retrograde transport at synaptic termini. Neuron 2012;74:344-60.
14. Moughamian AJ, Holzbaur EL. Dynactin is required for transport initiation from the distal axon. Neuron 2012;74:331-43.
15. Lazarus JE, Moughamian AJ, Tokito MK, Holzbaur EL. Dynactin subunit p150(Glued) is a neuron-specific anti-catastrophe factor. PLoS Biol 2013;11:e1001611.
16. Yu J, Lai C, Shim H, et al. Genetic ablation of dynactin p150Glued in postnatal neurons causes preferential degeneration of spinal motor neurons in aged mice. Mol Neurodegener 2018;13:10.
17. Levy JR, Sumner CJ, Caviston JP, et al. A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J Cell Biol 2006;172:733-45.
18. Ishikawa K, Saiki S, Furuya N, et al. P150glued-associated disorders are caused by activation of intrinsic apoptotic pathway. PLoS One 2014;9:e94645.
19. Mishima T, Ishikawa T, Imamura K, et al. Cytoplasmic aggregates of dynactin in iPSC-derived tyrosine hydroxylase-positive neurons from a patient with Perry syndrome. Parkinsonism Relat Disord 2016;30:67-72.
20. Lai C, Lin X, Chandran J, Shim H, Yang WJ, Cai H. The G59S mutation in p150(glued) causes dysfunction of dynactin in mice. J Neurosci 2007;27:13982-90.
21. Laird FM, Farah MH, Ackerley S, et al. Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci 2008;28:1997-2005.
22. Chevalier-Larsen ES, Wallace KE, Pennise CR, Holzbaur EL. Lysosomal proliferation and distal degeneration in motor neurons expressing the G59S mutation in the p150Glued subunit of dynactin. Hum Mol Genet 2008;17:1946-55.
23. Mishima T, Deshimaru M, Watanabe T, et al. Behavioral defects in a DCTN1G71A transgenic mouse model of Perry syndrome. Neurosci Lett 2018;666:98-103.
24. Deshimaru M, Mishima T, Watanabe T, et al. Behavioral profile in a Dctn1G71A knock-in mouse model of Perry disease. Neurosci Lett 2021;764:136234.
25. Wang L, Xie C, Greggio E, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 2008;28:3384-91.
26. Lin X, Parisiadou L, Gu XL, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron 2009;64:807-27.
27. Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. Biochem Pharmacol 1975;24:1639-41.
28. Liu G, Sgobio C, Gu X, et al. Selective expression of Parkinson’s disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Hum Mol Genet 2015;24:5299-312.
29. Yorgason JT, España RA, Jones SR. Demon voltammetry and analysis software: analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J Neurosci Methods 2011;202:158-64.
30. Felicio AC, Dinelle K, Agarwal PA, et al. In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Mov Disord 2014;29:1197-201.
31. Chung EJ, Hwang JH, Lee MJ, et al. Expansion of the clinicopathological and mutational spectrum of Perry syndrome. Parkinsonism Relat Disord 2014;20:388-93.
32. Nagatsu T, Nakashima A, Ichinose H, Kobayashi K. Human tyrosine hydroxylase in Parkinson’s disease and in related disorders. J Neural Transm (Vienna) 2019;126:397-409.
33. Mulvihill KG. Presynaptic regulation of dopamine release: role of the DAT and VMAT2 transporters. Neurochem Int 2019;122:94-105.
34. Wider C, Dickson DW, Stoessl AJ, et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 2009;15:281-6.
35. Tsuboi Y, Dickson DW, Nabeshima K, et al. Neurodegeneration involving putative respiratory neurons in Perry syndrome. Acta Neuropathol 2008;115:263-8.
36. Wang Q, Song S, Jiang L, Hong JS. Interplay among norepinephrine, NOX2, and neuroinflammation: key players in Parkinson’s disease and prime targets for therapies. Ageing Neur Dis 2021;1:6.
